较大剂量甲强龙冲击治疗重症哮喘的临床观察(1)
 |
| 第1页 |
参见附件(2689KB，3页)。
[摘要] 目的 观察较大剂量甲基强的松龙(甲强龙)治疗重症哮喘的临床疗效。方法 将125例重症支气管哮喘患者分3组进行治疗：A组在常规治疗基础上加用甲强龙120mg/次，1次/8h，静脉滴注；B组在常规治疗基础上加用甲强龙60mg/次，1次/8h，静脉滴注；C组在常规治疗基础上加用地塞米松10mg/次，2次/d，静脉滴注。结果 B组、C组临床症状改善天数、哮鸣音消失天数显著少于A组(P<0.05)；A组治疗后pH、PaO2、SaO2明显上升，与B组、C组相比有显著性差异(P<0.05)。结论 较大剂量(360mg/d)甲强龙冲击治疗重症哮喘有较好疗效，无明显副作用。
[关键词] 重症哮喘；甲基强的松龙；冲击治疗
[中图分类号] R562.2+5 [文献标识码] B[文章编号] 1673-9701(2011)20-85-02
Clinical Observation on Higher Dose Methylprednisolone for Shock Treatment of Severe Asthma
LI Yongqian1TAN Yijun2
1.Zijin County People's Hospital of Heyuan City in Guangdong Province， Zijin 517400， China； 2.The People's Hospital of Heyuan City in Guangdong Province， Heyuan 517000， China
[Abstract] Objective To observe the clinical curative effect of higher dose methylprednisolone for shock treatment of severe asthma. Methods 125 cases of intensive bronchus asthma patients were treated in three groups： Group A based on conventional treatment and combined with methylprednisolone 120 mg per 8 hours intravenous drip； Group B based on conventional treatment and combined with methylprednisolone 60 mg per 8 hours intravenous drip； Group C based on conventional treatment and added dexamethasone 10 mg per time， 2 times per day intravenous drip. Results Days of clinical symptom relief and wheezing disappearance of groups B and C were significantly less than days of group A (P<0.05). After treatment， pH， PaO2 and SaO2 of group A obviously increased， and had significant differences compared with groups B and C (P<0.05). Conclusion Shock treatment of severe asthma with higher dose (360mg/d) methylprednisolone has good curative effect and no obvious side effects.
[Key words] Severe asthma； Methylprednisolone； Shock treatment
重症哮喘是支气管哮喘最严重的类型，其病情重，严重者常出现意识模糊，进而危及生命，故尽快缓解哮喘持续状态是其治疗的关键。糖皮质激素是最有效的治疗药物之一，目前对糖皮质激素的剂型、剂量尚无明确的规定。2007年1月～2011年1月我们随机比较了甲基强的松龙(甲强龙)两种剂量及地塞米松治疗重症哮喘125例，现报道如下。
1资料与方法
1.1研究对象
125例均为支气管哮喘发作期患者，所选病例排除其他心肺疾病，无结缔组织系统、血液系统疾病，近期无发热病史，未使用激素治疗；其诊断标准符合2003年中华医学会呼吸病学分会制定的支气管哮喘急性发作期诊断标准[1]；其中男73例，女52例，年龄18～55岁，平均(33.35±10.64)岁。将125例患者随机分为3组，A组44例，男26例，女18例，平均年龄(34.18±10 ......
您现在查看是摘要介绍页，详见PDF附件(2689KB，3页)。